PDGF receptor mutations in human diseases.

Area of Science:

• Molecular biology
• Oncology
• Genetics

Background:

• Platelet-derived growth factor (PDGF) receptors, encoded by PDGFRA and PDGFRB, are proto-oncogenes involved in cell signaling.
• Mutations in PDGFRA are implicated in gastrointestinal stromal tumors (GISTs), gliomas, and inflammatory fibroid polyps.
• PDGFRB mutations drive myofibroma development and chromosomal rearrangements of either gene are linked to myeloid neoplasms.

Purpose of the Study:

• To review the expanding knowledge of PDGFRA and PDGFRB mutations in both cancerous and noncancerous diseases.
• To highlight the functional analysis of these variants and their therapeutic implications.
• To summarize the preclinical validation of tyrosine kinase inhibitors targeting PDGF receptors.

Main Methods:

• Literature review of studies on PDGFRA and PDGFRB mutations.
• Analysis of functional data for identified variants.
• Summary of preclinical validation of targeted therapies.

Main Results:

• PDGFRA and PDGFRB mutations are associated with a spectrum of diseases, including GISTs, gliomas, myofibromas, and myeloid neoplasms.
• Germline variants in PDGFRB are linked to noncancerous conditions like primary familial brain calcification, fusiform aneurysms, Kosaki overgrowth syndrome, and Penttinen premature aging syndrome.
• Gain-of-function and loss-of-function variants demonstrate the critical role of PDGF receptor signaling in human health.

Conclusions:

• Dysregulation of PDGFRA and PDGFRB signaling contributes to diverse pathologies.
• Targeting PDGF receptors with tyrosine kinase inhibitors, such as imatinib, represents a viable therapeutic strategy for multiple conditions.
• Further research into PDGF receptor biology will likely uncover additional roles and therapeutic opportunities.